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Triamcinolone is an intermediate-acting synthetic gluco-
corticoid-9 "-Fluoro- 16 "-hydroxyprednisolone. It is five times
more potent than hydrocortisone.  It was approved by FDA1
and patented for the treatment of perennial and seasonal
allergic rhinitis. Its mechanism of action includes multiple
anti-inflammatory actions such as reduced fluid trans-
udation, inhibition of anti-inflammatory cytokines and
interference with fibroblast and endothelial cell function.
Intraocular pharmacological considerations include its
minimally water-soluble suspension formulation, hence
prolonged action and lack of tissue toxicity noted in animal
and human studies.2
Recent developments have demonstrated the
importance of triamcinolone in the management of
ophthalmic conditions. Researchers and clinicians have
shown its efficacy in the management of posterior segment
diseases.  It is readily available and cheap in Nigeria,3-10
hence the need for ophthalmic practitioners to be aware of its
use and how to administer the medication appropriately. 
Indications for intravitreal triamcinolone include
primary treatment of macular oedema from diabetic
retinopathy, retinal vein occlusion and posterior uveitis. It
has also been found to be useful in cystoid macular oedema,
idiopathic juxtafoveal telangiectasia and neovascular age-
related macular degeneration.3-10
METHOD OF INTRAVITREAL ADMINISTRATION
Pre-injection Patient Selection and Evaluation
The injection is contraindicated in patients with glaucoma,
and better avoided in the presence of ocular surface
infections such as blepharitis, conjunctivitis and stye. This
will reduce the risk of endophthalmitis.
Anaesthesia: Topical anaesthesia is adequate, but for
uncooperative patients, we give peribulbar anaesthesia in
our centre.
Mydriasis: The pupil is dilated for indirect ophthalmoscopy
before, during and after injection.
The procedure is an aseptic procedure; we administer
the injection in the operating theatre in our centre.
Requirements
1. 1cc syringes – the insulin or tuberculin syringes can
be used with a 25, 26 or 27G needle





1. Cleaning of periorbital skin with povidone iodine
2. Heavy lid speculum and topical povidone iodine 5%
instillation
3. Use callipers to measure injection site from the limbus,
at pars plana, 4mm for phakics, 3.5mm for pseudo-
phakics and 3mm for aphakics.
4. Withdraw triamcinolone suspension with insulin
syringe and 21G needle.
a. Use fresh vial for injection. 
b. Clean top of vial with povidone or spirit. 
c. Shake vial well due to the suspension nature of
triamcinolone. 
d. Withdraw triamcinolone, and change needle to 25-
27G for injection
Injecting triamcinolone
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a. Cross-check calliper measurements at pars plana
b. Injection directed at the centre of vitreous cavity and
optic nerve head
c. See the needle before injecting
d. Watch the lens in phakic patients
Apply cotton bud to injection site to prevent reflux.
Anterior chamber paracentesis is performed if digital
IOP is high or arterial pulsation noted on indirect
ophthalmoscopy.
a. Use 25-27G needle, cotton bud to stabilize the eye
b. Watch the lens in phakics
c. It is avoided in aphakics as vitreous will come to
AC
Post-injection povidone iodine drops and indirect
ophthalmoscopy are mandatory to check for arterial
pulsation, a sign of optic nerve vascular compromise; if
present, repeat paracentesis.
• Pad the eye overnight, patient is advised to assume a
sitting position for the first 6 hrs to avoid triamcinolone
crystals settling on fovea. 
• The intraocular pressure should be checked within 24
hours; follow up is then scheduled for one week, one
month, three months and six monthly thereafter.
• Topical ciprofloxacin four times daily is recommended
in the first week of injection.
COMPLICATIONS OF INTRAVITREAL
TRIAMCINOLONE
Complications associated with intravitreal triamcinolone









PREPARATION OF COMMON INTRAVITREAL
INJECTIONS
1. Vancomycin 
Dose: 1mg in 0.1ml
• 500mg vial
• Add 5mls of saline
• 1ml = 100mg
• 0.1ml = 10mg , then make up to 1ml, = 10mg, then
take 0.1ml = 1mg
2. 
Ceftazidime
Dose:  2 - 2.25mg in 0.1ml
• 1000mg vial
• Add 10mls of saline
• Withdraw 0.1ml = 10mg
• Make up to 0.45ml with saline
• 0.45ml = 10mg
• 0.1ml = 2.22mg
3.  Amphotericin B
Dose: 5 microgram = 0.5mg in 0.1 ml
• 50mg vial
• Add 10mls of saline
• 1ml = 5mg
• 0.1ml = 0.5mg
4. Amikacin
Dose:  0.4mg in 0.1ml
• 500mg/ml  vial
• Withdraw 1 ml (500mg), make up to 2ml with
saline
• Withdraw  1.6ml = 400mg
• Add saline to make 10mls = 40mg/ml
• Withdraw 1ml (40mg) and make up to 10mls with
saline = 4mg/ml
• 0.1ml of this = 0.4mg 
5. Gentamicin
Dose: 0.2mg in 0.1 ml
• 40mg/ml vial
• Withdraw 0.5ml = 20mg
• Add saline to make 10mls = 2mg/ml
• 0.1ml of this = 0.2mg (200mcg) 













Dose: 2mg in 0.1ml
• 500mg vial 
• Add 10mls saline = 50mg/ml
• Withdraw 0.1ml (5mg), make up to 0.25ml with
saline  
• 0.1ml of this = 2mg.
75
TS Oluleye, O Ajayi
REFERENCES
1. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R.
The lack of toxicity of intravitreally administered
triamcinolone acetonide. Am J Ophthalmol 1981; 91: 785–8.
2. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal
injection of triamcinolone for diffuse diabetic macular edema.
Arch Ophthalmol 2003; 121: 57-61.
3. Jonas JB, Akkoyun I, Kreissig I, et al. Diffuse diabetic macular
edema treated by intravitreal triamcinolone acetonide: a
prospective comparative non randomized study. Br J
Ophthalmol 2005; 89: 321-6.
4. Massin P, Andren F, Haouchine B, et al. Intravitreal 
triamcinolone acetonide for diabetic diffuse macular edema:
preliminary results of a prospective controlled trial.
Ophthalmology 2004; 111: 218-24..
5. Sutter FKP, Simpson JM, Gillies MC. Intravitreal
triamcinolone for diabetic macular edema that persists after
laser treatment. Three month efficacy and safety results of a
prospective randomized, double masked, placebo-controlled
clinical trial. Ophthalmology 2004; 111: 2044-9. 
6. Bardak Y, Cekic O, Tig SU. Comparison of ICG-assisted ILM
peeling and triamcinolone-assisted posterior vitreous removal
in diffuse diabetic macular edema. Eye 2006; 20: 1357-1359.
7. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone
acetonide modulates permeability and intercellular adhesion
molecule-1 (ICAM-1) expression of the ECV304 cell line:
implications for macular degeneration. Clin Exp Immunol 2000;
121: 458.
8. Spaide RF, Soronson J, Maranan L. Photodynamic therapy
with verteporfin combined with intravitreal injection of
triamcinolone acetonide for choroidal neovascularization.
Ophthalmology 2005; 112: 301–304.
9. Young S, Larkin G, Branley M, Lightman S. Safety and
efficacy of intravitreal triamcinolone for cystoid macular
oedema in uveitis.Clin  Experiment Ophthalmol 2001; 29: 2–6.
10. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure
elevation after intravitreal triamcinolone acetonide injection.
Ophthalmology 2005; 112: 593–598.
11. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute
endophthalmitis following intravitreal triamcinolone
acetonide injection. Am J Ophthalmol 2003; 136: 791–796.
76
